loading
Sarepta Therapeutics Inc stock is traded at $20.22, with a volume of 9.54M. It is up +0.80% in the last 24 hours and up +48.51% over the past month. Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$20.06
Open:
$20.13
24h Volume:
9.54M
Relative Volume:
0.87
Market Cap:
$1.98B
Revenue:
$2.23B
Net Income/Loss:
$-248.39M
P/E Ratio:
-7.5167
EPS:
-2.69
Net Cash Flow:
$-697.55M
1W Performance:
-7.29%
1M Performance:
+48.51%
6M Performance:
-80.97%
1Y Performance:
-85.70%
1-Day Range:
Value
$19.41
$20.25
1-Week Range:
Value
$18.52
$22.05
52-Week Range:
Value
$10.41
$143.49

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name
Name
Sarepta Therapeutics Inc
Name
Phone
617-274-4000
Name
Address
215 FIRST STREET, CAMBRIDGE, MA
Name
Employee
1,372
Name
Twitter
@sarepta
Name
Next Earnings Date
2025-08-01
Name
Latest SEC Filings
Name
SRPT's Discussions on Twitter

Compare SRPT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SRPT
Sarepta Therapeutics Inc
20.22 2.05B 2.23B -248.39M -697.55M -2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-29-25 Upgrade Barclays Underweight → Equal Weight
Jul-29-25 Initiated Bernstein Mkt Perform
Jul-29-25 Reiterated H.C. Wainwright Sell
Jul-29-25 Upgrade JP Morgan Underweight → Neutral
Jul-29-25 Upgrade Oppenheimer Perform → Outperform
Jul-28-25 Downgrade Barclays Equal Weight → Underweight
Jul-25-25 Downgrade JP Morgan Neutral → Underweight
Jul-24-25 Initiated Citigroup Sell
Jul-23-25 Downgrade BofA Securities Neutral → Underperform
Jul-22-25 Downgrade Barclays Overweight → Equal Weight
Jul-21-25 Downgrade Deutsche Bank Buy → Hold
Jul-21-25 Downgrade Leerink Partners Outperform → Market Perform
Jul-21-25 Downgrade Mizuho Outperform → Neutral
Jul-21-25 Downgrade Needham Hold → Underperform
Jul-21-25 Downgrade UBS Buy → Neutral
Jul-18-25 Downgrade Needham Buy → Hold
Jun-20-25 Downgrade William Blair Outperform → Mkt Perform
Jun-18-25 Downgrade TD Cowen Buy → Hold
Jun-17-25 Initiated Wolfe Research Peer Perform
Jun-16-25 Downgrade BMO Capital Markets Outperform → Market Perform
Jun-16-25 Downgrade BofA Securities Buy → Neutral
Jun-16-25 Downgrade Cantor Fitzgerald Overweight → Neutral
Jun-16-25 Downgrade H.C. Wainwright Neutral → Sell
Jun-16-25 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-16-25 Downgrade Piper Sandler Overweight → Neutral
Jun-06-25 Upgrade Scotiabank Sector Perform → Sector Outperform
May-08-25 Downgrade Evercore ISI Outperform → In-line
Apr-11-25 Initiated Wells Fargo Overweight
Apr-02-25 Upgrade H.C. Wainwright Sell → Neutral
Mar-31-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-11-25 Initiated Deutsche Bank Hold
Nov-27-24 Reiterated Needham Buy
Nov-25-24 Initiated H.C. Wainwright Sell
Nov-07-24 Upgrade Cantor Fitzgerald Neutral → Overweight
Oct-21-24 Initiated Jefferies Buy
Oct-10-24 Resumed Raymond James Outperform
Jul-29-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-26-24 Downgrade Citigroup Buy → Neutral
May-31-24 Initiated Piper Sandler Overweight
May-28-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
May-14-24 Upgrade Oppenheimer Perform → Outperform
Jan-31-24 Initiated BMO Capital Markets Outperform
Dec-13-23 Resumed Citigroup Buy
Dec-12-23 Initiated Deutsche Bank Buy
Nov-21-23 Initiated Wedbush Outperform
Oct-31-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-31-23 Downgrade Oppenheimer Outperform → Perform
Jun-23-23 Downgrade Evercore ISI Outperform → In-line
Apr-26-23 Initiated SMBC Nikko Outperform
Apr-04-23 Initiated Citigroup Buy
Mar-01-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-22-22 Reiterated BTIG Research Buy
Dec-16-22 Upgrade UBS Neutral → Buy
Apr-04-22 Resumed Cantor Fitzgerald Overweight
Jan-05-22 Reiterated Needham Buy
Dec-09-21 Upgrade Oppenheimer Perform → Outperform
Nov-05-21 Upgrade JP Morgan Neutral → Overweight
Sep-15-21 Upgrade Guggenheim Neutral → Buy
Aug-05-21 Upgrade JP Morgan Underweight → Neutral
Jun-15-21 Initiated BTIG Research Buy
Apr-26-21 Resumed Credit Suisse Neutral
Jan-12-21 Downgrade Citigroup Buy → Neutral
Jan-11-21 Downgrade UBS Buy → Neutral
Jan-08-21 Downgrade JP Morgan Overweight → Underweight
Jan-08-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-08-21 Downgrade Raymond James Outperform → Mkt Perform
Nov-11-20 Initiated Berenberg Hold
Oct-28-20 Initiated UBS Buy
Aug-25-20 Initiated Raymond James Outperform
Aug-20-20 Downgrade Credit Suisse Outperform → Neutral
Mar-31-20 Initiated Mizuho Buy
Nov-01-19 Initiated Guggenheim Buy
Aug-21-19 Reiterated Needham Buy
Jul-09-19 Reiterated Morgan Stanley Overweight
Jul-01-19 Reiterated RBC Capital Mkts Outperform
Apr-12-19 Initiated Evercore ISI Outperform
Mar-11-19 Reiterated Credit Suisse Outperform
Oct-12-18 Initiated Bernstein Outperform
Oct-01-18 Initiated Cantor Fitzgerald Overweight
Sep-26-18 Reiterated RBC Capital Mkts Outperform
Sep-14-18 Resumed BofA/Merrill Buy
Sep-06-18 Initiated Credit Suisse Outperform
Aug-01-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18 Reiterated Robert W. Baird Outperform
Jun-20-18 Reiterated Needham Buy
Jun-19-18 Reiterated H.C. Wainwright Buy
View All

Sarepta Therapeutics Inc Stock (SRPT) Latest News

pulisher
Aug 20, 2025

Jim Cramer on Sarepta Therapeutics: "If it Goes Up, You Gotta Do Some Selling" - Yahoo Finance

Aug 20, 2025
pulisher
Aug 20, 2025

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Aug 20, 2025
pulisher
Aug 20, 2025

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.

Aug 20, 2025
pulisher
Aug 20, 2025

2025-08-20 | Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Contact Levi & Korsinsky Before August 25, 2025 to Join Class Action | NDAQ:SRPT | Press Release - Stockhouse

Aug 20, 2025
pulisher
Aug 20, 2025

SRPT Investors Have the Opportunity to Lead the Sarepta - GlobeNewswire

Aug 20, 2025
pulisher
Aug 20, 2025

SRPT Investors Have the Opportunity to Lead the Sarepta Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Morningstar

Aug 20, 2025
pulisher
Aug 20, 2025

BofA Securities Adjusts Price Target on Sarepta Therapeutics to $17 From $10, Maintains Underperform Rating - MarketScreener

Aug 20, 2025
pulisher
Aug 20, 2025

What MACD and RSI say about Sarepta Therapeutics Inc.Profit Target & Risk Controlled Swing Alerts - Newser

Aug 20, 2025
pulisher
Aug 20, 2025

Will Sarepta Therapeutics Inc. bounce back from current supportWeekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser

Aug 20, 2025
pulisher
Aug 19, 2025

Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com

Aug 19, 2025
pulisher
Aug 19, 2025

Sarepta Therapeutics, Inc. Investors: Please contact the - GlobeNewswire

Aug 19, 2025
pulisher
Aug 19, 2025

Sarepta Therapeutics, Inc. (SRPT) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 25, 2025 Deadline - Barchart.com

Aug 19, 2025
pulisher
Aug 19, 2025

Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky - GlobeNewswire

Aug 19, 2025
pulisher
Aug 19, 2025

Earnings visualization tools for Sarepta Therapeutics Inc.2025 EndofYear Setup & Intraday High Probability Alerts - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Burned by Sarepta Therapeutics, Inc.? Contact Levi & Korsinsky to SueWallSt and Fight Back - ACCESS Newswire

Aug 19, 2025
pulisher
Aug 19, 2025

SRPT’s Stock Dilemma: Sarepta Therapeutics Inc’s Market Performance and Outlook - investchronicle.com

Aug 19, 2025
pulisher
Aug 19, 2025

Shareholders that lost money on Sarepta Therapeutics, Inc.(SRPT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - Morningstar

Aug 19, 2025
pulisher
Aug 19, 2025

SRPT SECURITIES: Sarepta Therapeutics, Inc. Shareholders - GlobeNewswire

Aug 19, 2025
pulisher
Aug 19, 2025

Sarepta Therapeutics, Inc. $SRPT Shares Sold by Maryland State Retirement & Pension System - Defense World

Aug 19, 2025
pulisher
Aug 19, 2025

PNC Financial Services Group Inc. Has $149,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - Defense World

Aug 19, 2025
pulisher
Aug 18, 2025

Sarepta Therapeutics Inc. stock daily chart insightsJuly 2025 Trade Ideas & Safe Swing Trade Setup Alerts - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire

Aug 18, 2025
pulisher
Aug 18, 2025

Robbins LLP Reminds Sarepta Therapeutics, Inc. Stockholders - GlobeNewswire

Aug 18, 2025
pulisher
Aug 18, 2025

Contact The Gross Law Firm by August 25, 2025 Deadline to - GlobeNewswire

Aug 18, 2025
pulisher
Aug 18, 2025

Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue - Yahoo Finance

Aug 18, 2025
pulisher
Aug 18, 2025

Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff - GlobeNewswire

Aug 18, 2025
pulisher
Aug 18, 2025

Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - Newsfile

Aug 18, 2025
pulisher
Aug 18, 2025

Investors In Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - Barchart.com

Aug 18, 2025
pulisher
Aug 18, 2025

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders - Morningstar

Aug 18, 2025
pulisher
Aug 18, 2025

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire

Aug 18, 2025
pulisher
Aug 18, 2025

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar

Aug 18, 2025
pulisher
Aug 18, 2025

SRPT LOSSES: Sarepta Therapeutics, Inc. Investors with Losses are Encouraged to Contact BFA Law before Expiration of August 25 Class Action Deadline - Newsfile

Aug 18, 2025
pulisher
Aug 18, 2025

How the Moms and Dads of Patients Won Sarepta’s Drug a Reprieve - Bloomberg.com

Aug 18, 2025
pulisher
Aug 18, 2025

SRPT INVESTOR NOTICE: Robbins Geller Ruman & Dowd LLP - GlobeNewswire

Aug 18, 2025
pulisher
Aug 18, 2025

Will Sarepta Therapeutics Inc. outperform the marketPortfolio Update Summary & Pattern Based Trade Signal System - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Sarepta Therapeutics, Inc. $SRPT Shares Sold by LPL Financial LLC - Defense World

Aug 18, 2025
pulisher
Aug 18, 2025

SRPT LOSS ALERT: Sarepta Therapeutics, Inc. Investors with - GlobeNewswire

Aug 18, 2025
pulisher
Aug 18, 2025

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities LawsuitContact the DJS Law Group Before the Final DeadlineSRPT - MarketScreener

Aug 18, 2025
pulisher
Aug 17, 2025

How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com

Aug 17, 2025
pulisher
Aug 17, 2025

2025-08-17 | Securities Class Action Lawsuit Filed Against Sarepta Therapeutics, Inc. (SRPT)Levi & Korsinsky Represents Shareholders | NDAQ:SRPT | Press Release - Stockhouse

Aug 17, 2025
pulisher
Aug 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSRPT - FinancialContent

Aug 17, 2025
pulisher
Aug 17, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says - Defense World

Aug 17, 2025
pulisher
Aug 16, 2025

Sarepta Changes Course, Agrees to Pause Elevidys Shipments - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

SRPT IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, - GlobeNewswire

Aug 16, 2025
pulisher
Aug 16, 2025

Sarepta Therapeutics and the Biotech Litigation Landscape: Navigating Risk in a High-Stakes Sector - AInvest

Aug 16, 2025
pulisher
Aug 16, 2025

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - GlobeNewswire

Aug 16, 2025
pulisher
Aug 16, 2025

SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire

Aug 16, 2025
pulisher
Aug 16, 2025

BFA Law Notifies SAREPTA THERAPEUTICS, INC. (SRPT) Investors to Contact the Firm before the Upcoming August 25 Securities Fraud Class Action Deadline - Newsfile

Aug 16, 2025
pulisher
Aug 16, 2025

US Bancorp DE Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Aug 16, 2025
pulisher
Aug 15, 2025

SRPT FRAUD REMINDER: Sarepta Therapeutics, Inc. Stock Drop - GlobeNewswire

Aug 15, 2025
pulisher
Aug 15, 2025

Sarepta Therapeutics Faces Questions Over Its Key Gene Therapy - Finimize

Aug 15, 2025

Sarepta Therapeutics Inc Stock (SRPT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Sarepta Therapeutics Inc Stock (SRPT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Barry Richard
Director
May 16 '25
Option Exercise
32.63
12,350
402,981
2,966,667
Barry Richard
Director
May 13 '25
Option Exercise
19.23
20,246
389,359
2,954,317
Nicaise Claude
Director
Mar 12 '25
Option Exercise
25.18
9,746
245,404
30,303
Nicaise Claude
Director
Mar 12 '25
Sale
99.64
2,491
248,203
27,812
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):